Pierre Caloz Net Worth

The estimated Net Worth of Pierre Caloz is at least $1.21 Millón dollars as of 17 June 2024. Mr Caloz owns over 2,936 units of uniQure N.V stock worth over $632,917 and over the last 3 years he sold QURE stock worth over $574,050.

Mr Caloz QURE stock SEC Form 4 insiders trading

Mr has made over 8 trades of the uniQure N.V stock since 2022, according to the Form 4 filled with the SEC. Most recently he sold 2,936 units of QURE stock worth $14,122 on 17 June 2024.

The largest trade he's ever made was selling 15,117 units of uniQure N.V stock on 10 July 2023 worth over $171,729. On average, Mr trades about 3,307 units every 52 days since 2021. As of 17 June 2024 he still owns at least 115,707 units of uniQure N.V stock.

You can see the complete history of Mr Caloz stock trades at the bottom of the page.

Mr. Pierre Caloz biography

Pierre Caloz is the Chief Operating Officer at uniQure N.V.

What's Mr Caloz's mailing address?

Pierre's mailing address filed with the SEC is C/O UNIQURE N.V., PAASHEUVELWEG 25A, AMSTERDAM, P7, 11058BP.

Insiders trading at uniQure N.V

Over the last 8 years, insiders at uniQure N.V have traded over $35,572,573 worth of uniQure N.V stock. The most active insiders traders include Deventer Sander Van, Paula Soteropoulos y William Lewis. On average, uniQure N.V executives and independent directors trade stock every 14 days with the average trade being worth of $37,634. The most recent stock trade was executed by Walid Abi Saab on 26 June 2024, trading 1,447 units of QURE stock currently worth $6,309.

What does uniQure N.V do?

uniqure is delivering on the promise of gene therapy - single treatments with potentially curative results. we are leveraging our modular and validated technology platform to rapidly advance a pipeline of proprietary and partnered gene therapies to treat patients with severe genetic diseases.

Complete history of Mr Caloz stock trades at uniQure N.V

uniQure N.V executives and stock owners

uniQure N.V executives and other stock owners filed with the SEC include:

• Matthew Kapusta,
  Chief Executive Officer, Chief Financial Officer, Executive Director
• Robert Gut,
  Executive Director
• Alexander Kuta,
  Executive Vice President, Operations
• Maria Cantor,
  Senior Vice President, Investor Relations and Communications
• Matthew Craig Kapusta,
  CEO & Exec. Director
• Dr. Alexander E. Kuta Ph.D.,
  Exec. VP of Quality & Regulatory
• Dr. Ricardo Dolmetsch Ph.D.,
  Pres of R&D
• Christian Klemt,
  CFO, Principal Financial Officer & GM of Amsterdam Site
• David Meek,
  Non-Executive Independent Director
• Philip Astley-Sparke,
  Independent Non-Executive Chairman of the Board
• Jack Kaye,
  Non-Executive Independent Director
• Jeremy Springhorn,
  Non-Executive Independent Director
• Madhavan Balachandran,
  Non-Executive Independent Director
• Paula Soteropoulos,
  Non-Executive Independent Director
• Leonard Post,
  Director
• Ricardo Dolmetsch,
  President, Research and Development
• Erin Boyer,
  Chief People & Culture Office
• Richard Porter Ph.D.,
  SVP of R&D and GM of Corlieve
• Dr. Tamara Tugal Ph.D., MBA,
  Bus. Devel. Director
• Maria E. Cantor,
  Chief Communications Officer
• David Cerveny,
  Chief Legal Officer, Gen. Counsel & Sec.
• Pierre Caloz,
  Chief Operating Officer
• Prof. Hugo Katus,
  Chairman of Scientific Advisory Board and Managing Director of UniQure-Germany
• Rachelle Suzanne Jacques,
  Director
• Christian Meyer,
  Chief Medical Officer
• Harald Petry,
  Chief Scientific Officer
• Maiken Keson Brookes,
  General Counsel
• Jonathan Garen,
  Chief Business Officer
• David Schaffer,
  Director
• Paul E Firuta,
  Chief Commercial Officer
• William Lewis,
  Director
• Steven Zelenkofske,
  Chief Medical Officer
• Deventer Sander Van,
  EVP, Research & Product Dev.
• Scott T. Mc Millan,
  Chief Operating Officer
• Pierre Caloz,
  Chief Operating Officer
• Christian Klemt,
  Chief Financial Officer
• Jeannette Potts,
  Chief Legal Officer
• Walid Abi Saab,
  Chief Medical Officer